Abstract
Venom peptides offer enormous opportunity for the discovery of peptide drug leads. This review focusses on the potential of cone snails that have developed arrays of small peptides as part of highly evolved venoms used for prey capture and defence. Many of these peptides selectively modulate ion channels and transporters, making them a valuable source of new ligands for studying the role these targets play in normal and disease physiology. A number of these conopeptides reduce pain in animals models and several are now in preclinical and clinical development for the treatment of severe pain often associated with diseases such as cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Lewis RJ, Garcia ML. Therapeutic potential of venom peptides. Nature Reviews Drug Discovery 2003; 2:790–802.
Lewis RJ, Nielsen KJ, Craik DJ et al. Novel ω-conotoxins from Conus catus discriminate among neuronal calcium channel subtypes. J Biol Chem 2000; 275:35335–35344.
Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, N-type calcium-channel blockers, on behavior and antinociception in the formalin, and hot-plate tests in rats. Pain 1995; 60:83–90.
Smith M, Cabot PJ, Ross FB et al. The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain 2002; 96:119–127.
Nielsen K, Schroeder T, Lewis RJ. Structure-activity relationships of ω-conotoxins at N-type voltage-sensitive calcium channels. J Mol Recognition 2000; 13:55–70.
Schroeder CI, Smythe ML, Lewis RJ. Development of small molecules that mimic the binding of ω-conotoxins at the N-type voltage-gated calcium channel. Molec Diversity 2004; 8:127–134.
Wood JN, Boorman J. Voltage-gated sodium channel blockers; target validation and therapeutic potential. Curr Top Med Chem 2005; 5:529–537.
Ekberg J, Jayamanne A, Vaughan CW et al. μO-conotoxin MrVIB selectively blocks Na, 1.8 sensory neuron specific sodium channels and chronic pain without motor deficits. Proc Natl Acad Sci 2006; 103:17030–17035.
Nicke A, Wonnacott S, Lewis RJ. α-Conotoxins as tools for the elucidation of structure and function of neuronal nicotinic acetylcholine receptor subtypes. Eur J Biochem 2004; 271:2305–2319.
Sandall DW, Satkunanathan N, Keays DA et al. A novel α-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo Biochemistry 2003; 42:6904–11.
Sharpe IA, Gehrmann J, Loughnan ML et al. Two new classes of conopeptides inhibit the α1-adrenoceptor and noradrenaline transporter. Nature Neurosci 2001; 4:902–907.
Nielsen CK, Lewis RJ, Alewood D et al. Anti-allodynic efficacy of the ξ-conopeptide, Xen2174, in rats with neuropathic pain. Pain 2005; 118:112–124.
Paczkowski FA, Sharpe IA, Dutertre S et al. ξ-Conopeptide and tricyclic anti-depressant interactions at the norepinephrine transporter define a new transporter model. J Biol Chem 2007; 282:17837–17844.
Malmberg AB, Gilbert H, McCabe RT et al. Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain 2003; 101:109–116.
Craig AG, Norberg T, Griffin D et al. Contulakin-G, an O-glycosylated invertebrate neurotensin. J Biol Chem 1999; 274:13752–9.
Allen JW, Hofer K, McCumber D et al. An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs. Anesth Analg 2007; 104:1505–13.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Landes Bioscience and Springer Science+Business Media
About this chapter
Cite this chapter
Lewis, R.J. (2009). Conotoxin Venom Peptide Therapeutics. In: Guzmán, C.A., Feuerstein, G.Z. (eds) Pharmaceutical Biotechnology. Advances in Experimental Medicine and Biology, vol 655. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-1132-2_5
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1132-2_5
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-1131-5
Online ISBN: 978-1-4419-1132-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)